BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 26496271)

  • 21. Serologic testing with ANCA, ASCA, and anti-OmpC in children and young adults with Crohn's disease and ulcerative colitis: diagnostic value and correlation with disease phenotype.
    Zholudev A; Zurakowski D; Young W; Leichtner A; Bousvaros A
    Am J Gastroenterol; 2004 Nov; 99(11):2235-41. PubMed ID: 15555007
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pancreatic Autoantibodies Against CUZD1 and GP2 Are Associated with Distinct Clinical Phenotypes of Crohn's Disease.
    Michaels MA; Jendrek ST; Korf T; Nitzsche T; Teegen B; Komorowski L; Derer S; Schröder T; Baer F; Lehnert H; Büning J; Fellerman K; Sina C
    Inflamm Bowel Dis; 2015 Dec; 21(12):2864-72. PubMed ID: 26273818
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anti-Saccharomyces cerevisiae antibody does not differentiate between Crohn's disease and intestinal tuberculosis.
    Makharia GK; Sachdev V; Gupta R; Lal S; Pandey RM
    Dig Dis Sci; 2007 Jan; 52(1):33-9. PubMed ID: 17160471
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evidence of Crohn's disease-related anti-glycoprotein 2 antibodies in patients with celiac disease.
    Roggenbuck D; Vermeire S; Hoffman I; Reinhold D; Schierack P; Goihl A; von Arnim U; De Hertogh G; Polymeros D; Bogdanos DP; Bossuyt X
    Clin Chem Lab Med; 2015 Aug; 53(9):1349-57. PubMed ID: 25411995
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anti-Outer membrane protein C and anti-glycoprotein 2 antibodies in inflammatory bowel disease and their association with complicated forms of Crohn's disease.
    Kohoutova D; Drahosova M; Moravkova P; Rejchrt S; Bures J
    BMC Gastroenterol; 2014 Dec; 14():190. PubMed ID: 25551469
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pancreatic autoantibodies and autoantibodies against goblet cells in pediatric patients with inflammatory bowel disease.
    Kovacs M; Lakatos PL; Papp M; Jacobsen S; Nemes E; Polgar M; Solyom E; Bodi P; Horvath A; Muller KE; Molnar K; Szabo D; Cseh A; Dezsofi A; Arato A; Veres G
    J Pediatr Gastroenterol Nutr; 2012 Oct; 55(4):429-35. PubMed ID: 22465933
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pancreatic autoantibodies are associated with reactivity to microbial antibodies, penetrating disease behavior, perianal disease, and extraintestinal manifestations, but not with NOD2/CARD15 or TLR4 genotype in a Hungarian IBD cohort.
    Lakatos PL; Altorjay I; Szamosi T; Palatka K; Vitalis Z; Tumpek J; Sipka S; Udvardy M; Dinya T; Lakatos L; Kovacs A; Molnar T; Tulassay Z; Miheller P; Barta Z; Stocker W; Papp J; Veres G; Papp M;
    Inflamm Bowel Dis; 2009 Mar; 15(3):365-74. PubMed ID: 18972554
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Autoantibodies pANCA, GAB and PAB in inflammatory bowel disease: prevalence, characteristics and diagnostic value.
    Homsak E; Micetić-Turk D; Bozic B
    Wien Klin Wochenschr; 2010 May; 122 Suppl 2():19-25. PubMed ID: 20517666
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diagnostic and clinical significance of Crohn's disease-specific anti-MZGP2 pancreatic antibodies by a novel ELISA.
    Pavlidis P; Shums Z; Koutsoumpas AL; Milo J; Papp M; Umemura T; Lakatos PL; Smyk DS; Bogdanos DP; Forbes A; Norman GL
    Clin Chim Acta; 2015 Feb; 441():176-81. PubMed ID: 25512163
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diagnostic utility, disease activity, and disease phenotype correlation of serum ASCA, pANCA, and PR3-ANCA in pediatric inflammatory bowel disease.
    Kim JM; Choi YM; Jung SA; Yang HR
    J Pediatr (Rio J); 2024; 100(2):204-211. PubMed ID: 38012956
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ileal inflammation may trigger the development of GP2-specific pancreatic autoantibodies in patients with Crohn's disease.
    Pavlidis P; Romanidou O; Roggenbuck D; Mytilinaiou MG; Al-Sulttan F; Liaskos C; Smyk DS; Koutsoumpas AL; Rigopoulou EI; Conrad K; Forbes A; Bogdanos DP
    Clin Dev Immunol; 2012; 2012():640835. PubMed ID: 23118780
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diagnostic role and clinical correlates of anti-Saccharomyces cerevisiae antibodies (ASCA) and anti-neutrophil cytoplasmic antibodies (p-ANCA) in Italian patients with inflammatory bowel diseases.
    Saibeni S; Folli C; de Franchis R; Borsi G; Vecchi M
    Dig Liver Dis; 2003 Dec; 35(12):862-8. PubMed ID: 14703881
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anti-GP2 IgA autoantibodies are associated with poor survival and cholangiocarcinoma in primary sclerosing cholangitis.
    Jendrek ST; Gotthardt D; Nitzsche T; Widmann L; Korf T; Michaels MA; Weiss KH; Liaskou E; Vesterhus M; Karlsen TH; Mindorf S; Schemmer P; Bär F; Teegen B; Schröder T; Ehlers M; Hammers CM; Komorowski L; Lehnert H; Fellermann K; Derer S; Hov JR; Sina C
    Gut; 2017 Jan; 66(1):137-144. PubMed ID: 27406039
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diagnostic and clinical significance of antigen-specific pancreatic antibodies in inflammatory bowel diseases: A meta-analysis.
    Gkiouras K; Grammatikopoulou MG; Theodoridis X; Pagkalidou E; Chatzikyriakou E; Apostolidou AG; Rigopoulou EI; Sakkas LI; Bogdanos DP
    World J Gastroenterol; 2020 Jan; 26(2):246-265. PubMed ID: 31988587
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Autoantibodies against exocrine pancreas in Crohn's disease are directed against two antigens: the glycoproteins CUZD1 and GP2.
    Komorowski L; Teegen B; Probst C; Aulinger-Stöcker K; Sina C; Fellermann K; Stöcker W
    J Crohns Colitis; 2013 Nov; 7(10):780-90. PubMed ID: 23140841
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Familial and sporadic inflammatory bowel disease: comparison of clinical features and serological markers in a genetically homogeneous population.
    Halme L; Turunen U; Heliö T; Paavola P; Walle T; Miettinen A; Järvinen H; Kontula K; Färkkilä M
    Scand J Gastroenterol; 2002 Jun; 37(6):692-8. PubMed ID: 12126248
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease.
    Peeters M; Joossens S; Vermeire S; Vlietinck R; Bossuyt X; Rutgeerts P
    Am J Gastroenterol; 2001 Mar; 96(3):730-4. PubMed ID: 11280542
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association of Anti-glycan Antibodies and Inflammatory Bowel Disease Course.
    Paul S; Boschetti G; Rinaudo-Gaujous M; Moreau A; Del Tedesco E; Bonneau J; Presles E; Mounsef F; Clavel L; Genin C; Flourié B; Phelip JM; Nancey S; Roblin X
    J Crohns Colitis; 2015 Jun; 9(6):445-51. PubMed ID: 25895876
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Glycoprotein 2 antibodies in Crohn's disease.
    Roggenbuck D; Reinhold D; Werner L; Schierack P; Bogdanos DP; Conrad K
    Adv Clin Chem; 2013; 60():187-208. PubMed ID: 23724745
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-high mobility group box 1 and box 2 non-histone chromosomal proteins (HMGB1/HMGB2) antibodies and anti-Saccharomyces cerevisiae antibodies (ASCA): accuracy in differentially diagnosing UC and CD and correlation with inflammatory bowel disease phenotype.
    Takaishi H; Kanai T; Nakazawa A; Sugata F; Nikai A; Yoshizawa S; Hamamoto Y; Funakoshi S; Yajima T; Iwao Y; Takemura M; Ozaki S; Hibi T
    J Gastroenterol; 2012 Sep; 47(9):969-77. PubMed ID: 22644337
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.